Despite advances in detection, over 20% of CRC patients are diagnosed at the metastatic stage, which complicates treatment with chemotherapy and targeted therapies, such as those targeting vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) [2, 3]. The gene discussed is EGFR; the disease is colorectal carcinoma.